- Home
- BMRN vs PAYP Comparison
BMRN vs PAYP Comparison
Compare BMRN & PAYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | PAYP |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.4B |
| IPO Year | 1999 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BMRN | PAYP |
|---|---|---|
| Price | $58.97 | $14.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $88.22 | $25.54 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 05-04-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,313,646,000.00 | N/A |
| Revenue This Year | $15.02 | N/A |
| Revenue Next Year | $12.23 | $20.92 |
| P/E Ratio | $109.20 | ★ N/A |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $49.26 | $12.07 |
| 52 Week High | $66.28 | $24.89 |
Technical Indicators
Market Signals| Indicator | BMRN | PAYP |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 44.67 |
| Support Level | $53.32 | $12.07 |
| Resistance Level | $61.92 | $23.11 |
| Average True Range (ATR) | 1.49 | 0.99 |
| MACD | 0.19 | 0.30 |
| Stochastic Oscillator | 85.48 | 82.76 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About PAYP PayPay Corporation American Depository Shares
PayPay is a fintech company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.